Cytarabine (Synonyms: Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C)

Name: Cytarabine
Brand: MedChemExpress
SKU: HY-13605
Rating: 5.0 (95 reviews)

Cat. No.: HY-13605 Purity: 99.98%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Cytarabine, a nucleoside analog, causes S phase cell cycle arrest and inhibits DNA polymerase. Cytarabine inhibits DNA synthesis with an IC₅₀ of 16 nM. Cytarabine has antiviral effects against HSV. Cytarabine shows anti-orthopoxvirus activity.

For research use only. We do not sell to patients.

CAS No. : 147-94-4

Size	Stock	Quantity
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 95 publication(s) in Google Scholar

Other Forms of Cytarabine:

95 Publications Citing Use of MCE Cytarabine

Cell Proliferation/Viability Assay

: Cytarabine purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305. [Abstract]; FKA (Flavokawain A; HY-N2420) decreases the viability in AML cell lines. MV4-11, MOLM-13, THP-1, and U937 cells were treated with or without various concentrations of FKA (2.5, 5, 10, and 20 μg/mL) for 24 and 48 h, and cell viability was detected by the MTS assay. Treatment with Cytarabine (HY-13605; 7.3 μg/mL) was used as a positive control.

: Cytarabine purchased from MedChemExpress. Usage Cited in: Toxicol Appl Pharmacol. 2025 May:498:117305. [Abstract]; FKA (Flavokawain A; HY-N2420) targets primary AML blasts. Samples from AML patients were treated with or without various concentrations of FKA (2.5, 5, 10, and 20 μg/mL) for 48 h, and cell viability was detected by the MTS assay. Treatment with Cytarabine (HY-13605) was used as a positive control. Data were shown as mean ± SD from at least three independent experiments.

: Cytarabine purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2024 Sep 27:101770. [Abstract]; Cell viability of WiT49-parental and WiT49-PRC-1 cells treated with cytarabine. IC50 is shown in the figure. The WiT49-PRC-1 cells are 100-fold more sensitive to cytarabine and 20-fold more sensitive to alisertib than the parental WiT49 cells.

: Cytarabine purchased from MedChemExpress. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839. [Abstract]; TF-1 clones are incubated with 2 µM Cytarabine (araC) for up to 10 or 12 h, and cleaved caspase-3 is detected by immunoblot analysis.

: Cytarabine purchased from MedChemExpress. Usage Cited in: Leukemia. 2021 Oct;35(10):2827-2839. [Abstract]; TF-1 clones were incubated with 2 µM araC or 1 µM DNR for up to 10 or 12 h, respectively, and cleaved caspase-3 was detected by immunoblot analysis. GAPDH was used as loading control.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

View All Isoforms

RNASE L DNA Polymerases RNA Polymerases Helicases DNA Ligase

View All HSV Isoform Specific Products:

View All Isoforms

HSV-1 HSV-2 HSV

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

Microbial Metabolite

DNA Polymerase

HSV-1

Cellular Effect

Cell Line	Type	Value	Description	References
143B	IC₅₀	16.88 μM Compound: Cytarabine	Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay Cytotoxicity against human thymidine kinase deficient 143B cells after 72 hrs by SRB assay	[PMID: 27073055]
143B	IC₅₀	2.06 μM Compound: Cytarabine	Cytotoxicity against human 143B cells after 72 hrs by SRB assay Cytotoxicity against human 143B cells after 72 hrs by SRB assay	[PMID: 27073055]
A-375	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against A-375 cell line human melanoma Tested in vitro against A-375 cell line human melanoma	[PMID: 8277499]
A549	GI₅₀	0.2 μM Compound: Ara-C	Growth inhibition of human A549 cells after 24 hrs by WST-1 assay Growth inhibition of human A549 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
A549	IC₅₀	0.83 μM Compound: ara-C	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
A549	IC₅₀	1.2 μM Compound: Ara-C	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
A549	IC₅₀	1.75 μM Compound: Ara-C	Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human A549 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
A549	IC₅₀	1.9 μM Compound: 1, ara-C	Cytotoxicity against human A549 cells by sulforhodamine B method Cytotoxicity against human A549 cells by sulforhodamine B method	[PMID: 19691349]
A549	IC₅₀	1.9 μM Compound: 2, Ara-C	Cytotoxicity against human A549 cells by SRB assay Cytotoxicity against human A549 cells by SRB assay	[PMID: 24956556]
A549	IC₅₀	1.9 μM Compound: AraC	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 38716896]
A549	IC₅₀	202.57 μM Compound: CAR	Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay Anticancer activity against human A549 cells incubated for 48 hrs by MTT assay	[PMID: 38516604]
A549	IC₅₀	3.47 μM Compound: ara-C	Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
A549	IC₅₀	49.27 μg/mL Compound: CAR	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35963130]
A549	IC₅₀	620 μM Compound: cytarabine	Cytotoxicity against A549 cells after 72 hrs by SRB assay Cytotoxicity against A549 cells after 72 hrs by SRB assay	[PMID: 17419604]
AMML	IC₅₀	2.3 μM Compound: ara-C	Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia) Compound was tested for the inhibition of AMML (acute myelomonocytic leukemia)	[PMID: 3761322]
B16	IC₅₀	0.24 μg/mL Compound: Ara-C	In vitro inhibitory activity against Mouse melanoma (B16) cell line. In vitro inhibitory activity against Mouse melanoma (B16) cell line.	[PMID: 1995905]
B16	IC₅₀	30.62 μM Compound: Cytarabine	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	[PMID: 21620529]
B16	IC₅₀	49.22 μM Compound: Cytarabine	Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay Antiproliferative activity against mouse B16 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
BALL-1	GI₅₀	0.08 μM Compound: Ara-C	Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay Growth inhibition of human BALL-1 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
Bel-7402	IC₅₀	34.2 μM Compound: Ara-C	Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay Cytotoxicity against human Bel7402 cells after 24 hrs by MTT assay	[PMID: 20692841]
Bone marrow cell	GI₅₀	64.1 μM Compound: Cytarabine	Growth inhibition of human bone marrow cells Growth inhibition of human bone marrow cells	[PMID: 29995404]
CAKI-1	IC₅₀	> 5 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against renal CAKI-1 cells In vitro cytotoxicity was evaluated against renal CAKI-1 cells	[PMID: 10780904]
CCRF S-180	ED₅₀	0.2 μM Compound: ara-C	Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of S-180 cell lines by 50% after 72 hr incubation	[PMID: 1652024]
CCRF S-180	ED₅₀	0.2 μM Compound: ara-C	Effective dose to inhibit the replication of S180 cell line in vitro. Effective dose to inhibit the replication of S180 cell line in vitro.	[PMID: 1995894]
CCRF S-180	IC₅₀	25.43 μM Compound: Cytarabine	Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay	[PMID: 21620529]
CCRF S-180	IC₅₀	40.33 μM Compound: Cytarabine	Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay Antiproliferative activity against mouse S180 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
CCRF-CEM	EC₅₀	0.00561 μM Compound: cytarabine	Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	EC₅₀	0.0228 μM Compound: cytarabine	Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human CCRF-CEM/C2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
CCRF-CEM	ED₅₀	0.005 μM Compound: ara-C	Inhibit the replication of CCRF-CEM cell line in vitro. Inhibit the replication of CCRF-CEM cell line in vitro.	[PMID: 1995894]
CCRF-CEM	ED₅₀	0.006 μM Compound: ara-C	Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of CCRF-CEM cell lines by 50% after 72 hr incubation	[PMID: 1652024]
CCRF-CEM	ED₅₀	120 μM Compound: ara-C	Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-) Concentration required to inhibit replication of CCRF-CEM deoxycytidine kinase deficient variant CCRF-CEM(dCK-)	[PMID: 1652024]
CCRF-CEM	GI₅₀	0.09 μM Compound: Ara-C	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL) In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM without hPAP (0.2 unit/mL)	[PMID: 11597404]
CCRF-CEM	GI₅₀	0.0998 μM Compound: Ara-C	In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL) In vitro concentration required for 50% inhibition of growth of human leukemia cell line CCRF-CEM with hPAP (0.2 unit/mL)	[PMID: 11597404]
CCRF-CEM	IC₅₀	0.001 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive human CCRF-CEM cells after 3 days by MTT assay	[PMID: 19674903]
CCRF-CEM	IC₅₀	0.0037 μM Compound: araC	Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells	10.1016/S0960-894X(97)00044-9
CCRF-CEM	IC₅₀	0.006 μM Compound: Ara-C	Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human CCRF-CEM cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
CCRF-CEM	IC₅₀	0.024 μM Compound: ara-C, cytarabine	Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs Cytotoxicity against human CEM cells assessed as inhibition of cell proliferation after 48 hrs	[PMID: 20000418]
CCRF-CEM	IC₅₀	0.024 μM Compound: cytarabine	Cytotoxicity against human CEM cells after 2 days Cytotoxicity against human CEM cells after 2 days	[PMID: 19910080]
CCRF-CEM	IC₅₀	0.065 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of CCRF CEM leukemic cell lines in human.	[PMID: 1992123]
CCRF-CEM	IC₅₀	0.065 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines. In vitro inhibitory effect on growth of human T-cell acute lymphoblastoid leukemic CCRFCEM cell lines.	[PMID: 3373480]
CCRF-CEM	IC₅₀	0.09 μM Compound: 6	In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM). In vitro cytotoxicity of compounds were determined on Inhibition of human leukemia cell line(CCRF-CEM).	[PMID: 8917645]
CCRF-CEM	IC₅₀	0.32 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line. In vitro inhibitory activity against Human T-cell acute lymphoblastoid leukemia (CCRF CEM) cell line.	[PMID: 1995905]
CCRF-CEM	IC₅₀	6.0 x 10^-7 M Compound: Ara-C	Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines Cytotoxicity against CCRF-CEM human leukemic lymphoblastoid cell lines	[PMID: 6827546]
CCRF-CEM/ara-C	IC₅₀	0.0001 M Compound: Ara-C	Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines Cytotoxicity against CCRF-CEM/ara-C human leukemic lymphoblastoid cell lines	[PMID: 6827546]
CCRF-HSB-2	IC₅₀	0.0086 μg/mL Compound: araC	Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells. Antiproliferative effects on CCRF-HSB-2 (human leukemia) cells.	[PMID: 9216836]
CCRF-HSB-2	IC₅₀	0.017 μg/mL Compound: Ara-C	Antitumor activity against human CCRF-HSB2 cells by MTT assay Antitumor activity against human CCRF-HSB2 cells by MTT assay	[PMID: 18723355]
CCRF-HSB-2	IC₅₀	0.017 μg/mL Compound: AraC	Growth inhibition of human CCRF-HSB-2 cells by MTT method Growth inhibition of human CCRF-HSB-2 cells by MTT method	[PMID: 18819815]
CCRF-HSB-2	IC₅₀	0.047 μg/mL Compound: Ara-C	Antitumor activity against human CCRF-HSB2 cells by modified MTT assay Antitumor activity against human CCRF-HSB2 cells by modified MTT assay	[PMID: 17644399]
CCRF-HSB-2	IC₅₀	0.047 μg/mL Compound: Ara-C	Antitumor activity against human CCRF-HSB2 cells by MTT assay Antitumor activity against human CCRF-HSB2 cells by MTT assay	[PMID: 17962027]
CCRF-HSB-2	IC₅₀	0.15 μM Compound: ara-C	Growth inhibition of human CCRF-HSB-2 cells by MTT assay Growth inhibition of human CCRF-HSB-2 cells by MTT assay	[PMID: 17049252]
CML/BC	IC₅₀	0.21 μM Compound: ara-C	Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis) Compound was tested for the inhibition of CML/BC(chronic myeloid leukemia, blast crisis)	[PMID: 3761322]
COLO 320	IC₅₀	0.04 μM Compound: ara-c	Tested in vitro against colo-320 human colon adenocarcinoma Tested in vitro against colo-320 human colon adenocarcinoma	[PMID: 8277499]
DLD-1	IC₅₀	> 5 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against colon DLD-1 cells In vitro cytotoxicity was evaluated against colon DLD-1 cells	[PMID: 10780904]
Glioblastoma cell line	IC₅₀	> 100 μM Compound: ara-C	Compound was tested for the inhibition of glioblastoma Compound was tested for the inhibition of glioblastoma	[PMID: 3761322]
H22	IC₅₀	25.98 μM Compound: Cytarabine	Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay	[PMID: 21620529]
H22	IC₅₀	37.82 μM Compound: Cytarabine	Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay Antiproliferative activity against mouse H22 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
HCT-116	GI₅₀	0.12 μM Compound: Ara-C	Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay Growth inhibition of against human HCT116 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
HCT-116	IC₅₀	0.1 μM Compound: Ara-C	Antitumor activity against human HCT116 cells after 24 hrs by MTT assay Antitumor activity against human HCT116 cells after 24 hrs by MTT assay	[PMID: 20211564]
HCT-116	IC₅₀	2.42 μM Compound: Ara-C	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
HCT-116	IC₅₀	4.4 μM Compound: Ara-C	Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human HCT116 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
HCT-116	IC₅₀	5.3 μM Compound: 1, ara-C	Cytotoxicity against human HCT116 cells by sulforhodamine B method Cytotoxicity against human HCT116 cells by sulforhodamine B method	[PMID: 19691349]
HCT-116	IC₅₀	5.3 μM Compound: 2, Ara-C	Cytotoxicity against human HCT116 cells by SRB assay Cytotoxicity against human HCT116 cells by SRB assay	[PMID: 24956556]
HCT-116	IC₅₀	5.3 μM Compound: AraC	Cytotoxicity against human HCT-116 cells Cytotoxicity against human HCT-116 cells	[PMID: 38716896]
HL-60	EC₅₀	0.6572 μM Compound: cytarabine	Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HL-60	ED₅₀	0.047 μM Compound: ara-C	Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+) Anticancer activity was evaluated for the compound against parent promyelocytic leukemia cell line (HL-60-GHPRT+/dCK+)	[PMID: 3027329]
HL-60	ED₅₀	30 μM Compound: ara-C	Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined Anticancer activity of the compound against ara-C resistant promyelocytic leukemia cell line that is Cyd-kinase deficient (HL-60-HGPRT-/dCK-) is determined	[PMID: 3027329]
HL-60	IC₅₀	0.029 μg/mL Compound: ara-C	The cytotoxic activity in HL-60 cells The cytotoxic activity in HL-60 cells	[PMID: 9371251]
HL-60	IC₅₀	0.049 μM Compound: Ara-C	Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human HL60 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
HL-60	IC₅₀	0.08 μM Compound: citarabine	In vitro inhibitory concentration against proliferation of HL60 cells In vitro inhibitory concentration against proliferation of HL60 cells	[PMID: 12877593]
HL-60	IC₅₀	0.118 μM Compound: Ara-C, Cytarabine	Cytotoxicity against human HL60 cells after 48 hrs by MTT assay Cytotoxicity against human HL60 cells after 48 hrs by MTT assay	[PMID: 19321234]
HL-60	IC₅₀	0.13 μM Compound: ara-C	Compound was tested for the inhibition of human HL60 Leukemia Compound was tested for the inhibition of human HL60 Leukemia	[PMID: 3761322]
HL-60	IC₅₀	0.185 μM Compound: Cytarabine	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 30114661]
HL-60	IC₅₀	0.35 μM Compound: citarabine	In vitro concentration required to induce apoptosis in HL60R cells In vitro concentration required to induce apoptosis in HL60R cells	[PMID: 12877593]
HL-60	IC₅₀	0.76 μM Compound: ara-C	Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line	[PMID: 12954073]
HL-60	IC₅₀	> 0.1 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line. In vitro inhibitory activity against Human promyelocytic leukemia (HL-60) cell line.	[PMID: 1995905]
HL-60	IC₅₀	> 0.1 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of HL60 leukemic cell lines in human.	[PMID: 1992123]
HL60/MX2	EC₅₀	0.2612 μM Compound: cytarabine	Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay Cytotoxicity against human HL60/MX2 cells after 48 hrs by cell titer-blue assay	[PMID: 19743858]
HOS-TE85	IC₅₀	10.7 μM Compound: ara-c	Tested in vitro against MNNG/HOS cell line human osteosarcoma Tested in vitro against MNNG/HOS cell line human osteosarcoma	[PMID: 8277499]
HOS-TE85	IC₅₀	2.6 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells In vitro inhibitory effect measured against human osteosarcoma MNNG-HOS tumor cells	[PMID: 2002478]
HT-1080	IC₅₀	0.13 μg/mL Compound: 2	In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells In vitro inhibitory effect measured against human fibrosarcoma HT1080 tumor cells	[PMID: 2002478]
HT-1080	IC₅₀	0.53 μM Compound: ara-c	Tested in vitro against HT1080 cell line human fibrosarcoma Tested in vitro against HT1080 cell line human fibrosarcoma	[PMID: 8277499]
HT-29	IC₅₀	66 nM Compound: cytosine arabinoside	Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 2778449]
HUVEC	GI₅₀	0.23 μM Compound: Ara-C	Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay Growth inhibition of HUVEC cells after 72 hrs by WST-1 assay	[PMID: 22264170]
HeLa	ED₅₀	0.05 μg/mL Compound: AraC	Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis Cytotoxicity against human HeLa cells after 48 hrs by Coulter counter analysis	[PMID: 178873]
HeLa	GI₅₀	0.18 μM Compound: Ara-C	Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay Growth inhibition of human HeLa cells after 24 hrs by WST-1 assay	[PMID: 22264170]
HeLa	IC₅₀	0.23 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human HeLa S3 cells Cytotoxicity against human HeLa S3 cells	[PMID: 10425135]
HeLa	IC₅₀	0.26 μM Compound: ara-C, cytarabine	Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs Cytotoxicity against human HeLa cells assessed as inhibition of cell proliferation after 48 hrs	[PMID: 20000418]
HeLa	IC₅₀	0.95 μM Compound: ARA	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 29886320]
HeLa	IC₅₀	3.54 μM Compound: Cytarabine	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 23867603]
HeLa	IC₅₀	3.54 μM Compound: Cytarabine	Cytotoxicity against human HeLa cells after 72 hrs by SRB assay Cytotoxicity against human HeLa cells after 72 hrs by SRB assay	[PMID: 27073055]
HeLa	IC₅₀	3.54 μM Compound: ara-C	Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HeLa cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HeLa	IC₅₀	3.54 μM Compound: ara-C	Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HeLa	IC₅₀	464.433 μM Compound: Ara-C, Cytarabine	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19321234]
HeLa S3	ED₅₀	2.13 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human HeLaS3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
HepG2	IC₅₀	0.2 μM Compound: Ara-C	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 20692841]
HepG2	IC₅₀	2.86 μM Compound: Cytarabine	Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay	[PMID: 27073055]
HepG2	IC₅₀	2.86 μM Compound: ara-C	Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human HepG2 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
HepG2	IC₅₀	2.86 μM Compound: ara-C	Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
HepG2	IC₅₀	26.23 μM Compound: Cytarabine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 21620529]
HepG2	IC₅₀	38.1 μM Compound: Cytarabine	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
Jurkat E6.1	IC₅₀	0.018 μM Compound: Cytarabine	Antiproliferative activity against human Jurkat E6-1 cells Antiproliferative activity against human Jurkat E6-1 cells	[PMID: 30114661]
K562	IC₅₀	0.05 μM Compound: 1, ara-C	Cytotoxicity against human K562 cells by sulforhodamine B method Cytotoxicity against human K562 cells by sulforhodamine B method	[PMID: 19691349]
K562	IC₅₀	0.05 μM Compound: 2, Ara-C	Cytotoxicity against human K562 cells by SRB assay Cytotoxicity against human K562 cells by SRB assay	[PMID: 24956556]
K562	IC₅₀	0.05 μM Compound: AraC	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 38716896]
K562	IC₅₀	14 μM Compound: Ara-C	Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay Cytotoxicity against human K562 cells assessed as cell viability after 48 hrs by celltiter-blue assay	[PMID: 22582991]
K562	IC₅₀	24.29 μM Compound: Cytarabine	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 21620529]
K562	IC₅₀	3.2 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of K562 leukemic cell lines in human.	[PMID: 1992123]
K562	IC₅₀	3.2 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines. In vitro inhibitory effect on growth of human chronic myelogenous leukemic K562 cell lines.	[PMID: 3373480]
K562	IC₅₀	33.5 μM Compound: Ara-C	Cytotoxicity against human K562 cells after 24 hrs by MTT assay Cytotoxicity against human K562 cells after 24 hrs by MTT assay	[PMID: 20692841]
K562	IC₅₀	43.61 μM Compound: Cytarabine	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	10.1039/C0MD00208A
K562	IC₅₀	500 mM Compound: ara-C	Antiproliferative activity against human K562 cells Antiproliferative activity against human K562 cells	[PMID: 18571290]
K562	IC₅₀	500 nM Compound: ara-c	Inhibition of cell growth against human myeloid leukemia K562(S) cells Inhibition of cell growth against human myeloid leukemia K562(S) cells	[PMID: 10560743]
KB	ED₅₀	0.99 μg/mL Compound: Cytosine arabinoside	Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis Cytotoxicity against human KB cells assessed as inhibition of protein biosynthesis	[PMID: 21194944]
KB	ED₅₀	2.84 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique Cytotoxicity against human KB cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
KB	IC₅₀	0.14 μg/mL Compound: Ara-C	Growth inhibition of human KB cells by MTT assay Growth inhibition of human KB cells by MTT assay	[PMID: 18055068]
KB	IC₅₀	0.23 μg/mL Compound: Ara-C	Antitumor activity against human KB cells by modified MTT assay Antitumor activity against human KB cells by modified MTT assay	[PMID: 17644399]
KB	IC₅₀	0.23 μg/mL Compound: Ara-C	Antitumor activity against human KB cells by MTT assay Antitumor activity against human KB cells by MTT assay	[PMID: 17962027]
KB	IC₅₀	0.42 μg/mL Compound: AraC	Growth inhibition of human KB cells by MTT method Growth inhibition of human KB cells by MTT method	[PMID: 18819815]
KB	IC₅₀	0.64 μM Compound: ara-C	Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line Tested for in vitro cytotoxicity against KB human oral epidermoid carcinoma cell line	[PMID: 8277500]
KB	IC₅₀	0.7 μM Compound: ara-C	Growth inhibition of human KB cells by MTT assay Growth inhibition of human KB cells by MTT assay	[PMID: 17049252]
KB	IC₅₀	0.73 μg/mL Compound: Ara-C	Antitumor activity against human KB cells by MTT assay Antitumor activity against human KB cells by MTT assay	[PMID: 18723355]
KB	IC₅₀	0.81 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human KB cells Cytotoxicity against human KB cells	[PMID: 10425135]
KB	IC₅₀	0.99 μg/mL Compound: Cytarabine	Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human KB cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
KB	IC₅₀	2.3 μM Compound: ara-c	Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells	[PMID: 8277499]
KB	IC₅₀	30.5 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line. In vitro inhibitory activity against Human oral epidermoid carcinoma (KB) cell line.	[PMID: 1995905]
KB	IC₅₀	4.07 μM Compound: Cytarabine	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 23867603]
KB	IC₅₀	4.07 μM Compound: Cytarabine	Cytotoxicity against human KB cells after 72 hrs by SRB assay Cytotoxicity against human KB cells after 72 hrs by SRB assay	[PMID: 27073055]
KB	IC₅₀	4.07 μM Compound: ara-C	Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human KB cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
KB	IC₅₀	4.07 μM Compound: ara-C	Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
KHOS-321H	IC₅₀	0.27 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells In vitro inhibitory effect measured against human osteosarcoma KHOS-321H tumor cells	[PMID: 2002478]
KKLS	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against KKLS human stomach adenocarcinoma Tested in vitro against KKLS human stomach adenocarcinoma	[PMID: 8277499]
L02	IC₅₀	0.17 μM Compound: ARA	Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 29886320]
L02	IC₅₀	0.21 μM Compound: ARA	Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay Cytotoxicity against human L02 cells incubated for 72 hrs by MTT assay	[PMID: 30852384]
L1210	ED₅₀	0.03 μM Compound: ara-C	Inhibition of thymidylate synthase in L1210 cells Inhibition of thymidylate synthase in L1210 cells	[PMID: 3027329]
L1210	ED₅₀	0.05 μM Compound: ara-C	Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of L1210 cell lines by 50% after 72 hr incubation	[PMID: 1652024]
L1210	ED₅₀	0.05 μM Compound: ara-C	Effective dose to inhibit the replication of L1210 cell line in vitro. Effective dose to inhibit the replication of L1210 cell line in vitro.	[PMID: 1995894]
L1210	ED₅₀	0.1 μM Compound: ara-C	Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay Cytotoxicity against mouse L1210 cells assessed as growth inhibition measured at 72 hrs by trypan blue exclusion assay	[PMID: 118258]
L1210	ED₅₀	0.1 μM Compound: ara-C	In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line In vitro antiproliferative activity was measured in mouse myeloma L1210 cell line	[PMID: 7143370]
L1210	ED₅₀	0.19 μM Compound: ara-C	In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours. In vitro cytotoxicity with cleavage by phosphodiesterase-I concentration for 50% loss of viability was determined at 72 hours.	[PMID: 3968680]
L1210	ED₅₀	2.76 μg/mL Compound: cytosine arabinoside	Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique Cytotoxicity against mouse L1210 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
L1210	IC₅₀	0.0004 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive mouse L1210 cells after 3 days by MTT assay	[PMID: 19674903]
L1210	IC₅₀	0.01 μM Compound: 1	Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr) Inhibition of L1210 lymphoid leukemia cells 48 hr after administration (length of preincubation=0 hr)	[PMID: 1527783]
L1210	IC₅₀	0.01 μM Compound: 1	Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr) Inhibition of L1210 lymphoid leukemia cells 72 hr after administration (length of preincubation=0 hr)	[PMID: 1527783]
L1210	IC₅₀	0.024 μM Compound: ara-C, cytarabine	Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs Cytotoxicity against mouse L1210 cells assessed as inhibition of cell proliferation after 48 hrs	[PMID: 20000418]
L1210	IC₅₀	0.024 μM Compound: cytarabine	Cytotoxicity against mouse L1210 cells after 2 days Cytotoxicity against mouse L1210 cells after 2 days	[PMID: 19910080]
L1210	IC₅₀	0.031 μM Compound: araC	Tested for its antiproliferative activity on murine leukemia L1210 cells Tested for its antiproliferative activity on murine leukemia L1210 cells	10.1016/S0960-894X(97)00044-9
L1210	IC₅₀	0.036 μM Compound: ara-C	Inhibitory concentration on multidrug-resistant L1210 leukemia cells. Inhibitory concentration on multidrug-resistant L1210 leukemia cells.	[PMID: 1906107]
L1210	IC₅₀	0.036 μM Compound: ara-C	Inhibitory concentration on parentral (sensitive) L1210 leukemia cells. Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.	[PMID: 1906107]
L1210	IC₅₀	0.05 μM Compound: ara-c	Tested in vitro inhibitory activity against murine leukemia L1210 Tested in vitro inhibitory activity against murine leukemia L1210	[PMID: 8277499]
L1210	IC₅₀	0.08 μM Compound: araC	Inhibitory activity against murine leukemia L1210 cells Inhibitory activity against murine leukemia L1210 cells	[PMID: 1992143]
L1210	IC₅₀	0.097 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse. Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.	[PMID: 1992123]
L1210	IC₅₀	0.097 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines. In vitro inhibitory effect on growth of mouse leukemic L1210 cell lines.	[PMID: 3373480]
L1210	IC₅₀	0.1 μM Compound: 1	Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr) Inhibition of L1210 lymphoid leukemia cells 24 hr after administration (length of preincubation=0 hr)	[PMID: 1527783]
L1210	IC₅₀	0.12 μM Compound: ara-C	Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse Tested in vitro for cytotoxicity against L1210 leukemia cell line in mouse	[PMID: 8277500]
L1210	IC₅₀	0.17 μM Compound: Ara-C	Anticancer activity carried out in vitro against murine leukemia L1210 Anticancer activity carried out in vitro against murine leukemia L1210	[PMID: 11356110]
L1210	IC₅₀	103 μM Compound: AraC, cytarabine	Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay Cytotoxicity against deoxycytidine kinase deficient and nucleoside analogue-resistant mouse L1210 10K cells after 3 days by MTT assay	[PMID: 19674903]
MCF7	IC₅₀	0.004 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive human MCF7 cells after 3 days by MTT assay	[PMID: 19674903]
MCF7	IC₅₀	0.04 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-resistant human MCF7 1K cells overexpressing ribonucleotide reductase after 3 days by MTT assay	[PMID: 19674903]
MCF7	IC₅₀	0.62 μM Compound: ara-c	Tested in vitro against MCF-7 human breast adenocarcinoma Tested in vitro against MCF-7 human breast adenocarcinoma	[PMID: 8277499]
MCF7	IC₅₀	0.93 μg/mL Compound: Cytarabine	Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay Cytotoxicity against human MCF7 cells assessed as cell survival after 72 hrs by sulforhodamine B colorimetric assay	[PMID: 21945463]
MCF7	IC₅₀	1.03 μM Compound: Ara-C	Anticancer activity carried out in vitro against breast carcinoma MCF-7 Anticancer activity carried out in vitro against breast carcinoma MCF-7	[PMID: 11356110]
MCF7	IC₅₀	3.82 μM Compound: Cytarabine	Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay	[PMID: 23867603]
MCF7	IC₅₀	3.82 μM Compound: Cytarabine	Cytotoxicity against human MCF7cells after 72 hrs by SRB assay Cytotoxicity against human MCF7cells after 72 hrs by SRB assay	[PMID: 27073055]
MCF7	IC₅₀	3.82 μM Compound: ara-C	Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
MCF7	IC₅₀	> 20 μM Compound: Cytarabine	Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay Cytotoxicity against human MCF7 cells assessed as cell growth inhibition incubated for 48 hrs by AlamarBlue assay	[PMID: 35665692]
MCF7	IC₅₀	>= 100 μM Compound: Ara-C	Antitumor activity against human MCF7 cells after 24 hrs by MTT assay Antitumor activity against human MCF7 cells after 24 hrs by MTT assay	[PMID: 20211564]
MDA-MB-231	IC₅₀	1.37 μM Compound: Ara-C	Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
MDA-MB-231	IC₅₀	10.49 μM Compound: Ara-C	Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
MES-SA	IC₅₀	1.7 μM Compound: AraC, cytarabine	Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay Cytotoxicity against deoxynucleoside analogue-sensitive human MESSA cells after 3 days by MTT assay	[PMID: 19674903]
MKN-28	IC₅₀	4.5 μg/mL Compound: 2	In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells In vitro inhibitory effect measured against human stomach adenocarcinoma MKN-28 tumor cells	[PMID: 2002478]
MKN-45	IC₅₀	57.6 μM Compound: ara-c	Tested in vitro against MKN-45 human stomach adenocarcinoma Tested in vitro against MKN-45 human stomach adenocarcinoma	[PMID: 8277499]
MOLT-3	ED₅₀	2.67 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human TMOLT3 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
MOLT-4	IC₅₀	0.03 μM Compound: araC	Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells	10.1016/S0960-894X(97)00044-9
MOLT-4	IC₅₀	0.056 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line. In vitro inhibitory activity against Human T-cell acute lymphoblastic leukemia (MOLT-4) cell line.	[PMID: 1995905]
MOLT-4	IC₅₀	0.056 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of MOLT-4 leukemic cell lines in human.	[PMID: 1992123]
MOLT-4	IC₅₀	0.056 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines. In vitro inhibitory effect on growth of human T-cell acute lymphoblastic leukemic MOLT 4 cell lines.	[PMID: 3373480]
MOLT-4	IC₅₀	0.65 μM Compound: Ara-C	Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8 Anticancer activity carried out in vitro against human T-lymphocyte Molt4/C8	[PMID: 11356110]
MOLT-4	IC₅₀	1 μM Compound: Ara-C	Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay Antitumor activity against human MOLT4 cells after 24 hrs by MTT assay	[PMID: 20211564]
MOLT-4	IC₅₀	4.0 x 10^-7 M Compound: Ara-C	Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines Cytotoxicity against MOLT-4 human leukemic lymphoblastoid cell lines	[PMID: 6827546]
MPC-11	ED₅₀	0.99 μM Compound: ara-C	In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line In vitro antiproliferative activity was measured in mouse myeloma MPC-11 cell line	[PMID: 7143370]
MV4-11	IC₅₀	3.36 μM Compound: AraC	Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay Antiproliferative activity against wild type FLT3 expressing human MV411 cells after 72 hrs by WST8 assay	[PMID: 20153646]
NCC	IC₅₀	0.13 μg/mL Compound: 2	In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells In vitro inhibitory effect measured against human renal cell carcinoma NCC-nu tumor cells	[PMID: 2002478]
NCI-H23	IC₅₀	1 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1 In vitro cytotoxicity was evaluated against lung NCI-H23 cells; 1 x 10E1	[PMID: 10780904]
NCI-H460	IC₅₀	0.1 μM Compound: Ara-C	Antitumor activity against human H460 cells after 24 hrs by MTT assay Antitumor activity against human H460 cells after 24 hrs by MTT assay	[PMID: 20211564]
NHDF	IC₅₀	4.99 μM Compound: ara-C	Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay Cytotoxicity against HDF assessed as reduction in cell survival after 72 hrs by sulforhodamine B assay	[PMID: 27501415]
NHDF	IC₅₀	4.99 μM Compound: ara-C	Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
NUGC-3	GI₅₀	0.25 μM Compound: Ara-C	Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay Growth inhibition of human NUGC3 cells after 24 hrs by WST-1 assay	[PMID: 22264170]
Non-small cell lung cancer cell line	IC₅₀	34 μM Compound: ara-C	Compound was tested for the inhibition of non- small cell lung cancer Compound was tested for the inhibition of non- small cell lung cancer	[PMID: 3761322]
OST	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against OST human osteosarcoma Tested in vitro against OST human osteosarcoma	[PMID: 8277499]
P388	ED₅₀	0.02 μM Compound: ara-C	Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation Concentration required to inhibit replication of P388 cell lines by 50% after 72 hr incubation	[PMID: 1652024]
P388	ED₅₀	0.02 μM Compound: ara-C	Effective dose to inhibit the replication of P388 cell line in vitro. Effective dose to inhibit the replication of P388 cell line in vitro.	[PMID: 1995894]
P388	IC₅₀	0.14 μM Compound: Ara-C	Anticancer activity carried out in vitro against murine leukemia P388 Anticancer activity carried out in vitro against murine leukemia P388	[PMID: 11356110]
P388	IC₅₀	1233 nM Compound: cytosine arabinoside	Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay	[PMID: 2778449]
PBMC	IC₅₀	181 μM Compound: Cytarabin	Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay Cytotoxicity against human PBMC cells assessed as inhibition of cell growth incubated for 24 to 48 hrs by MTT assay	[PMID: 38064359]
PC-13	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line. In vitro inhibitory activity against Human lung large-cell carcinoma (PC-13) cell line.	[PMID: 1995905]
PC-13	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against PC-13 human lung large cell carcinoma Tested in vitro against PC-13 human lung large cell carcinoma	[PMID: 8277499]
PC-14	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line. In vitro inhibitory activity against Human lung adenocarcinoma (PC-14) cell line.	[PMID: 1995905]
PC-14	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma PC14 solid cell lines.	[PMID: 1992123]
PC-3	IC₅₀	0.81 μM Compound: ara-C	Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
PC-3	IC₅₀	48.4 μM Compound: Ara-C	Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human PC3 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
PC-3	IC₅₀	50.51 μM Compound: Ara-C	Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human PC3 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
PC-3	IC₅₀	55.9 μM Compound: 1, ara-C	Cytotoxicity against human PC3 cells by sulforhodamine B method Cytotoxicity against human PC3 cells by sulforhodamine B method	[PMID: 19691349]
PC-3	IC₅₀	55.9 μM Compound: 2, Ara-C	Cytotoxicity against human PC3 cells by SRB assay Cytotoxicity against human PC3 cells by SRB assay	[PMID: 24956556]
PC-3	IC₅₀	55.9 μM Compound: AraC	Cytotoxicity against human PC-3 cells Cytotoxicity against human PC-3 cells	[PMID: 38716896]
PC-6	IC₅₀	50 μg/mL Compound: 2	In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells In vitro inhibitory effect measured against human lung small-cell carcinoma PC-6 tumor cells	[PMID: 2002478]
PC-6	IC₅₀	50 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line. In vitro inhibitory activity against Human lung small-cell carcinoma (PC-6) cell line.	[PMID: 1995905]
PC-8	IC₅₀	0.28 μg/mL Compound: 2	In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells In vitro inhibitory effect measured against human lung adenocarcinoma PC-8 tumor cells	[PMID: 2002478]
PC-8	IC₅₀	1.1 μM Compound: ara-c	Tested in vitro against PC-8 human lung adenocarcinoma Tested in vitro against PC-8 human lung adenocarcinoma	[PMID: 8277499]
PC-9	IC₅₀	1.6 μg/mL Compound: 2	In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells In vitro inhibitory effect measured against human lung adenocarcinoma PC-9 tumor cells	[PMID: 2002478]
PC-9	IC₅₀	6.6 μM Compound: ara-c	Tested in vitro against PC-9 human lung adenocarcinoma Tested in vitro against PC-9 human lung adenocarcinoma	[PMID: 8277499]
PC10	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line. In vitro inhibitory activity against Human lung squamous cell carcinoma (PC-10) cell line.	[PMID: 1995905]
PC10	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma PC10 solid cell lines.	[PMID: 1992123]
PC10	IC₅₀	> 100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10). In vitro inhibitory effect on growth of human lung squamous cell carcinoma cell lines (PC10).	[PMID: 3373480]
QG-95	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against QG-95 human squamous cell carcinoma Tested in vitro against QG-95 human squamous cell carcinoma	[PMID: 8277499]
RPMI 6410	IC₅₀	6.0 x 10^-6 M Compound: Ara-C	Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines Cytotoxicity against RPMI-6410 human leukemic lymphoblastoid cell lines	[PMID: 6827546]
RS4-11	IC₅₀	0.26 μM Compound: AraC	Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay Antiproliferative activity against human RS4:11 cells having FLT3-ITD mutation after 72 hrs by WST8 assay	[PMID: 20153646]
SAOS-2	IC₅₀	2.7 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells In vitro inhibitory effect measured against human osteosarcoma SAOS-2 tumor cells	[PMID: 2002478]
SF-268	IC₅₀	7.68 x 10^-3 μM Compound: Cytarabine	Cytotoxicity against human SF268 cells by MTT assay Cytotoxicity against human SF268 cells by MTT assay	[PMID: 19345581]
SF-268	IC₅₀	7.68 μM Compound: Cytarabine	Cytotoxicity against human SF268 cells after 3 days by MTT assay Cytotoxicity against human SF268 cells after 3 days by MTT assay	[PMID: 20356655]
SK-BR-3	IC₅₀	0.87 μM Compound: ara-C	Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
SK-ES1	IC₅₀	0.09 μg/mL Compound: 2	In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells In vitro inhibitory effect measured against human osteosarcoma SK-ES-1 tumor cells	[PMID: 2002478]
SK-HEP1	IC₅₀	1.8 μM Compound: Ara-C	Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human SKHEP1 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
SK-HEP1	IC₅₀	2.12 μM Compound: Ara-C	Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human SKHEP1 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
SK-MEL-28	IC₅₀	1 μM Compound: Ara-C	In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells In vitro cytotoxicity was evaluated against melanoma SK-MEL-28 cells	[PMID: 10780904]
SK-MEL-28	IC₅₀	11.1 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human melanoma (P-36) cell line. In vitro inhibitory activity against Human melanoma (P-36) cell line.	[PMID: 1995905]
SK-OV-3	IC₅₀	0.99 μM Compound: ara-C	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
SMMC-7721	IC₅₀	0.013 μM Compound: ARA	Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 29886320]
SMMC-7721	IC₅₀	0.0271 μM Compound: ARA	Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay Cytotoxicity against human SMMC7721 cells incubated for 72 hrs by MTT assay	[PMID: 30852384]
SNB-7	IC₅₀	1 μM Compound: Ara-C	In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1 In vitro cytotoxicity was evaluated againstCNS SNB-7 cells; 1 x 10E1	[PMID: 10780904]
SNU-638	IC₅₀	0.15 μM Compound: 1, ara-C	Cytotoxicity against human SNU638 cells by sulforhodamine B method Cytotoxicity against human SNU638 cells by sulforhodamine B method	[PMID: 19691349]
SNU-638	IC₅₀	0.15 μM Compound: 2, Ara-C	Cytotoxicity against human SNU638 cells by SRB assay Cytotoxicity against human SNU638 cells by SRB assay	[PMID: 24956556]
SNU-638	IC₅₀	0.15 μM Compound: AraC	Cytotoxicity against human SNU-638 cells Cytotoxicity against human SNU-638 cells	[PMID: 38716896]
SNU-638	IC₅₀	1.08 μM Compound: Ara-C	Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay Cytotoxicity against human SNU638 cells assessed as decrease in cell viability after 72 hrs by SRB assay	[PMID: 29906687]
SNU-638	IC₅₀	3.98 μM Compound: Ara-C	Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay Cytotoxicity against human SNU638 cells assessed as inhibition of cell proliferation after 72 hrs by sulforhodamine B assay	[PMID: 26010585]
ST-KM-1	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against ST-KM human stomach adenocarcinoma Tested in vitro against ST-KM human stomach adenocarcinoma	[PMID: 8277499]
SW-620	IC₅₀	30 μM Compound: Ara-C	Antitumor activity against human SW620 cells after 24 hrs by MTT assay Antitumor activity against human SW620 cells after 24 hrs by MTT assay	[PMID: 20211564]
SW1573	IC₅₀	10500 μM Compound: cytarabine	Cytotoxicity against SW1573 cells after 72 hrs by SRB assay Cytotoxicity against SW1573 cells after 72 hrs by SRB assay	[PMID: 17419604]
SW48	IC₅₀	> 410 μM Compound: ara-c	Tested in vitro against SW-48 human colon adenocarcinoma Tested in vitro against SW-48 human colon adenocarcinoma	[PMID: 8277499]
SW480	ED₅₀	3.42 μg/mL Compound: cytosine arabinoside	Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique Cytotoxicity against human SW480 cells after 3 days by trypan blue exclusion technique	[PMID: 1800632]
SW480	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line. In vitro inhibitory activity against Human colon adenocarcinoma (SW-480) cell line.	[PMID: 1995905]
SW480	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma SW 480 solid cell lines.	[PMID: 1992123]
SW480	IC₅₀	> 100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480). In vitro inhibitory effect on growth of human colon adenocarcinoma cell lines (SW480).	[PMID: 3373480]
Small cell lung cancer cell line	IC₅₀	> 100 μM Compound: ara-C	Compound was tested for the inhibition of small cell lung cancer Compound was tested for the inhibition of small cell lung cancer	[PMID: 3761322]
T-24	IC₅₀	0.5 μg/mL Compound: 2	In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells In vitro inhibitory effect measured against human bladder transitional cell carcinoma T-24 tumor cells	[PMID: 2002478]
T-24	IC₅₀	0.5 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line. In vitro inhibitory activity against Human bladder transitional-cell carcinoma (T-24) cell line.	[PMID: 1995905]
T-24	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma T24 solid cell lines.	[PMID: 1992123]
T-24	IC₅₀	> 100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24). In vitro inhibitory effect on growth of human bladder transitional-carcinoma cell lines (T24).	[PMID: 3373480]
T47D	IC₅₀	2.7 μM Compound: 1, ara-C	Cytotoxicity against human T47D cells by sulforhodamine B method Cytotoxicity against human T47D cells by sulforhodamine B method	[PMID: 19691349]
T47D	IC₅₀	2.7 μM Compound: AraC	Cytotoxicity against human T47D cells Cytotoxicity against human T47D cells	[PMID: 38716896]
T47D	IC₅₀	2.72 μM Compound: 2, Ara-C	Cytotoxicity against human T47D cells by SRB assay Cytotoxicity against human T47D cells by SRB assay	[PMID: 24956556]
TE-2	IC₅₀	> 100 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line. In vitro inhibitory activity against Human esophagus adenocarcinoma (TE-2) cell line.	[PMID: 1995905]
TE-2	IC₅₀	> 100 μg/mL Compound: ara-C	Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines. Concentration required for 50% inhibition of human lung squamous cell carcinoma TE2 solid cell lines.	[PMID: 1992123]
TE-2	IC₅₀	> 100 μg/mL Compound: ara-C	In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2). In vitro inhibitory effect on growth of human esophagus adenocarcinoma cell lines (TE2).	[PMID: 3373480]
U-87MG ATCC	CC₅₀	0.19 μM Compound: 16	Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay Cytotoxicity against human U-87 MG cells measured after 3 days by Celltiter-glo assay	[PMID: 35123007]
U-87MG ATCC	IC₅₀	0.85 μM Compound: ara-C	Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay	[PMID: 32663707]
U-87MG ATCC	IC₅₀	2.88 μM Compound: ara-C	Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay	[PMID: 31400940]
U-937	IC₅₀	0.002 μM Compound: Cytarabine	Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability measured after 3 days by CCK8 assay	[PMID: 30954427]
U-937	IC₅₀	0.31 μg/mL Compound: ara-C	Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human. Concentration required for 50% inhibition of cell growth of U937 leukemic cell lines in human.	[PMID: 1992123]
U-937	IC₅₀	0.46 μg/mL Compound: Ara-C	In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line. In vitro inhibitory activity against Human histiocytic lymphoma (U-937) cell line.	[PMID: 1995905]
Vero	CC₅₀	4.8 μg/mL Compound: Ara-C	Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay	[PMID: 12444692]
Vero	EC₅₀	1.6 μg/mL Compound: Ara-C	Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV1 F infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	[PMID: 12444692]
Vero	EC₅₀	3 μg/mL Compound: Ara-C	Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay Antiviral activity against HSV2 MS infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay	[PMID: 12444692]
WI-38	IC₅₀	493.17 μM Compound: CAR	Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay Cytotoxicity against human WI-38 cells incubated for 48 hrs by MTT assay	[PMID: 38516604]
WI-38	IC₅₀	> 100 μg/mL Compound: CAR	Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay Antiproliferative activity against human WI-38 cells measured after 48 hrs by MTT assay	[PMID: 35963130]

In Vitro

Cytarabine is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC₅₀ of 16 nM^[1].
Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity^[3].
Cytarabine is highly effective against acute leukaemias, which causes the Cytarabine teristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

243.22

Formula

C₉H₁₃N₃O₅

CAS No.

147-94-4

Appearance

Solid

Color

White to off-white

SMILES

O=C1N=C(C=CN1[C@H]2[C@@H](O)[C@H](O)[C@@H](CO)O2)N

Structure Classification

Others

Initial Source

Microorganisms

Endogenous metabolite

Xerocomus nigromaculatus

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 17.3 mg/mL (71.13 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.1115 mL	20.5575 mL	41.1150 mL
5 mM	0.8223 mL	4.1115 mL	8.2230 mL
10 mM	0.4112 mL	2.0558 mL	4.1115 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (8.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (411.15 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (283 KB) SDS (557 KB)

COA (252 KB) HNMR (260 KB) RP-HPLC (205 KB) LCMS (92 KB) Elemental Analysis Report (110 KB)

Handling Instructions (2659 KB)

References

[1]. Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1(2): p. 112-6. [Content Brief]

[2]. Besirli, C.G., et al. Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10(9): p. 1045-58. [Content Brief]

[3]. Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70(6): p. 1762-7. [Content Brief]

[4]. Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58(6): p. 730-3. [Content Brief]

[5]. Shepshelovich D, et al. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. Br J Clin Pharmacol. 2015 Apr;79(4):685-91. [Content Brief]

[6]. Renis HE. Antiviral activity of cytarabine in herpesvirus-infected rats. Antimicrob Agents Chemother. 1973 Oct;4(4):439-44. [Content Brief]

[7]. Gruffaz M, Zhou S, Vasan K, et al. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. mBio. 2018;9(3):e00756-18. Published 2018 May 8. [Content Brief]

[8]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Animal Administration
^[3]

Pregnant rats are injected intraperitoneally (i.p.) with 250 mg/kg of Cytarabine on Day 13 of gestation (GD13). Under the conditions of this experiment, congenital anomalies and growth retardation are detected at a high rate in perinatal fetuses, although the incidence of fetal death is not markedly increased. At 1, 3, 6, 9, 12, 24, and 48 h after the treatment, six dams each are killed by heart puncture under ether anesthesia, and the placentas are collected. As controls, six pregnant rats are injected i.p. with an equivalent volume of PBS on GD13 and killed at the same time point as Cytarabine-treated groups. Of the six dams obtained at each time point, three are used for histopathological analyses and three for reverse transcription-polymerase chain reaction (RT-PCR) analysis.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Tobias, S.C. and R.F. Borch, Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm, 2004. 1(2): p. 112-6. [Content Brief]

[2]. Besirli, C.G., et al. Cytosine arabinoside rapidly activates Bax-dependent apoptosis and a delayed Bax-independent death pathway in sympathetic neurons. Cell Death Differ, 2003. 10(9): p. 1045-58. [Content Brief]

[3]. Yamauchi, H., et al., Involvement of p53 in 1-beta-D-arabinofuranosylcytosine-induced trophoblastic cell apoptosis and impaired proliferation in rat placenta. Biol Reprod, 2004. 70(6): p. 1762-7. [Content Brief]

[4]. Richel, D.J., et al., Comparison of the antileukaemic activity of 5 aza-2-deoxycytidine and arabinofuranosyl-cytosine in rats with myelocytic leukaemia. Br J Cancer, 1988. 58(6): p. 730-3. [Content Brief]

[5]. Shepshelovich D, et al. Pharmacodynamics of cytarabine induced leucopenia: a retrospective cohort study. Br J Clin Pharmacol. 2015 Apr;79(4):685-91. [Content Brief]

[6]. Renis HE. Antiviral activity of cytarabine in herpesvirus-infected rats. Antimicrob Agents Chemother. 1973 Oct;4(4):439-44. [Content Brief]

[7]. Gruffaz M, Zhou S, Vasan K, et al. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications. mBio. 2018;9(3):e00756-18. Published 2018 May 8. [Content Brief]

[8]. Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.1115 mL	20.5575 mL	41.1150 mL	102.7876 mL
	5 mM	0.8223 mL	4.1115 mL	8.2230 mL	20.5575 mL
	10 mM	0.4112 mL	2.0558 mL	4.1115 mL	10.2788 mL
	15 mM	0.2741 mL	1.3705 mL	2.7410 mL	6.8525 mL
	20 mM	0.2056 mL	1.0279 mL	2.0558 mL	5.1394 mL
	25 mM	0.1645 mL	0.8223 mL	1.6446 mL	4.1115 mL
	30 mM	0.1371 mL	0.6853 mL	1.3705 mL	3.4263 mL
	40 mM	0.1028 mL	0.5139 mL	1.0279 mL	2.5697 mL
	50 mM	0.0822 mL	0.4112 mL	0.8223 mL	2.0558 mL
	60 mM	0.0685 mL	0.3426 mL	0.6853 mL	1.7131 mL

Cytarabine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cytarabine147-94-4Cytosine β-D-arabinofuranoside Cytosine Arabinoside Ara-CDNA/RNA SynthesisNucleoside Antimetabolite/AnalogHSVAutophagyEndogenous MetaboliteApoptosisOrthopoxvirusHerpes simplex virusInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Cytarabine (Synonyms: Cytosine β-D-arabinofuranoside; Cytosine Arabinoside; Ara-C)

Customer Review

Other Forms of Cytarabine:

Cytarabine Related Antibodies

95 Publications Citing Use of MCE Cytarabine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All DNA/RNA Synthesis Isoform Specific Products:

View All HSV Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Cytarabine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Cytarabine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report